

Revised 11 Mar. 2008 (Vers. 1.1)

**INTENDED USE**

The *Borrelia burgdorferi* IgM ELISA kit is an enzyme-linked immunosorbent assay (ELISA) for the qualitative presumptive detection of IgM antibodies to *Borrelia burgdorferi* in human serum. This ELISA test should only be used for patients with signs and symptoms that are consistent with Lyme disease. Equivocal or positive results must be supplemented by testing with a standardized Western Blot procedure. Positive supplemental results are supportive evidence of exposure to *B. burgdorferi* and can be used to support a clinical diagnosis of Lyme disease.

**SIGNIFICANCE AND BACKGROUND**

*Borrelia burgdorferi* is a spirochete that causes Lyme disease. The organism is transmitted by ticks of the genus *Ixodes*. In endemic areas, these ticks are commonly found on vegetation and animals such as deer, mice, dogs, horses, and birds. *B. burgdorferi* infection shares features with other spirochetal infections (diseases caused by three genera in humans: *Treponema*, *Borrelia*, and *Leptospira*). Skin is the portal of entry for *B. burgdorferi* and the tick bite often causes a characteristic rash called erythema migrans (EM). EM develops around the tick bite in 60% to 80% of patients. Spirochetemia occurs early with wide spread dissemination through tissue and body fluids. Lyme disease occurs in stages, often with intervening latent periods and with different clinical manifestations.

In Lyme disease there are generally three stages of disease often with overlapping symptoms. Symptoms vary according to the sites affected by the infection such as joints, skin, central nervous system, heart, eye, bone, spleen, and kidney. Late disease is most often associated with arthritis or CNS syndromes. Asymptomatic subclinical infection is possible and infection may not become clinically evident until the later stages.

Patients with early infection produce IgM antibodies during the first few weeks after onset of EM and produce IgG antibodies more slowly (1). Although IgM only may be detected during the first month after onset of illness, the majority of patients develop IgG antibodies within one month. Both IgG and IgM antibodies can remain detectable for years.

Isolation of *B. burgdorferi* from skin biopsy, blood, and spinal fluid has been reported (2). However, these direct culture detection methods may not be practical in the large scale diagnosis of Lyme borreliosis.

Serological testing methods for antibodies to *B. burgdorferi* include indirect fluorescent antibody (IFA) staining, immunoblotting, and enzyme immunoassay (EIA).

*B. burgdorferi* is antigenically complex with strains that vary considerably. Early antibody responses often are to flagellum which has cross reactive components. Patients in early stages of infection may not produce detectable levels of antibody. Also, early antibiotic therapy after EM may diminish or abrogate good antibody response. Some patients may never generate detectable antibody levels. Thus, serological tests for antibodies to *B. burgdorferi* are known to have low sensitivity and specificity and because of such inaccuracy, these tests cannot be relied upon for establishing a diagnosis of Lyme disease (3,4).

In 1994, the Second National Conference on Serological diagnosis of Lyme disease recommended a two-step testing system toward standardizing laboratory serologic testing for *B. burgdorferi*. Because EIA and IFA methods were not sufficiently specific to support clinical diagnosis, it was recommended that positive or equivocal results from a sensitive EIA or IFA (first step) should be further tested, or supplemented, by using a standardized Western Blot method (second step) for detecting antibodies to *B. burgdorferi* (Western Blot assays

Revised 11 Mar. 2008 (Vers. 1.1)



for antibodies to *B. burgdorferi* are supplemental rather than confirmatory because their specificity is less than optimal, particularly for detecting IgM). Two-step positive results provide supportive evidence of exposure to *B. burgdorferi*, which could support a clinical diagnosis of Lyme disease but should not be used as a sole criterion for diagnosis.

### PRINCIPLE OF THE ELISA ASSAY

The DRG® International, Inc. *Borrelia burgdorferi* ELISA test system is designed to detect IgM class antibodies to *B. burgdorferi* in human sera. Wells of plastic microwell strips are sensitized by passive absorption with *B. burgdorferi* antigen. The test procedure involves three incubation steps:

1. Test sera are diluted with the Sample Diluent provided. The Sample Diluent contains anti-human IgG which precipitates and removes IgG and rheumatoid factor from the sample leaving IgM free to react with the immobilized antigen. During sample incubation, any antigen specific IgM antibody in the sample will bind to the immobilized antigen. The plate is washed to remove unbound antibody and other serum components.
2. Peroxidase Conjugated goat anti-human IgM ( $\mu$  chain specific) is added to the wells and the plate is incubated. The Conjugate will react with IgM antibody immobilized on the solid phase in step 1. The wells are washed to remove unbound Conjugate.
3. The microwells containing immobilized peroxidase Conjugate are incubated with peroxidase Substrate Solution. Hydrolysis of the Substrate by peroxidase produces a color change. After a period of time the reaction is stopped and the color intensity of the solution is measured photometrically. The color intensity of the solution depends upon the antibody concentration in the original test sample.

### MATERIALS PROVIDED

Each kit contains the following components in sufficient quantities to perform the number of tests indicated on packaging label. **Note:** All reactive reagents contain sodium azide as a preservative at a concentration of 0.1% (w/v).

Plate. 96 wells configured in twelve 1x8-well strips coated with inactivated *B. burgdorferi* (B31 strain) antigen. The strips are packaged in a strip holder and sealed in an envelope with desiccant.

Conjugate. Conjugated (horseradish peroxidase) goat anti-human IgM ( $\mu$  chain specific). Ready to use. One, 15 mL vial with a white cap.

Positive Control (Human Serum). One, 0.35 mL vial with a red cap.

Calibrator (Human Serum). One, 0.5 mL vial with a blue cap.

Negative Control (Human Serum). One, 0.35 mL vial with a green cap.

Absorbent Solution. One 12 mL bottle containing goat anti-human IgG ( $\gamma$  chain specific) and phosphate-buffered-saline, (pH 7.2.  $\pm$  0.2). Ready to use.

Sample diluent. One 30 mL bottle (green cap) containing Tween-20, bovine serum albumin and phosphate-buffered-saline, (pH 7.2  $\pm$  0.2). Green solution, ready to use. Note: Shake Well Before Use. Preservative added.

TMB. One 15 mL amber bottle (amber cap) containing 3,3',5,5' -tetramethylbenzidine(TMB). Ready to use. Contains DMSO < 15% (w).

Revised 11 Mar. 2008 (Vers. 1.1)



Stop solution. One 15 mL bottle (red cap) containing 1M H<sub>2</sub>SO<sub>4</sub>. 0.7M HCl. Ready to use.

Wash buffer concentrate (10X): dilute 1 part concentrate + 9 parts deionized or distilled water. One 100 mL bottle (clear cap) containing a 10X concentrated phosphate-buffered-saline and Tween-20 solution (blue solution). NOTE: 1X solution will have a pH of 7.2 ± 0.2.

**Note:** Kit also contains:

1. Component list containing lot specific information is inside the kit box.
2. Package insert providing instructions for use.

## PRECAUTIONS

1. For *In Vitro* Diagnostic Use.
2. Normal precautions exercised in handling laboratory reagents should be followed. In case of contact with eyes, rinse immediately with plenty of water and seek medical advice. Wear suitable protective clothing, gloves, and eye/face protection. Do not breathe vapor. Dispose of waste observing all local, state, and federal laws.
3. The wells of the ELISA plate do not contain viable organisms. However, the strips should be considered POTENTIALLY BIOHAZARDOUS MATERIALS and handled accordingly.
4. The human serum controls are POTENTIALLY BIOHAZARDOUS MATERIALS. Source materials from which these products were derived were found negative for HIV-1 antigen, HBsAg and for antibodies against HCV and HIV by approved test methods. However, since no test method can offer complete assurance that infectious agents are absent, these products should be handled at the Biosafety Level 2 as recommended for any potentially infectious human serum or blood specimen in the Centers for Disease Control/National Institutes of Health manual "Biosafety in Microbiological and Biomedical Laboratories": current edition; and OSHA's Standard for Bloodborne Pathogens (16).
5. The sample diluent, controls, wash buffer, absorbent, and conjugate contain sodium azide at a concentration of 0.1% (w/v). Sodium azide has been reported to form lead or copper azides in laboratory plumbing which may cause explosions on hammering. To prevent, rinse sink thoroughly with water after disposing of solution containing sodium azide.
6. Adherence to the specified time and temperature of incubations is essential for accurate results. **All reagents must be allowed to reach room temperature (20-25°C) before starting the assay.** Return unused reagents to refrigerated temperature immediately after use.
7. Improper washing could cause false positive or false negative results. Be sure to minimize the amount of any residual wash solution; (e.g., by blotting or aspiration) before adding Conjugate or Substrate. Do not allow the wells to dry out between incubations.
8. The Stop Solution is TOXIC. Causes burns. Toxic by inhalation, in contact with skin and if swallowed. In case of accident or if you feel unwell, seek medical advice immediately.
9. The TMB Solution is HARMFUL Irritating to eyes, respiratory system and skin.
10. The Wash Buffer concentrate is an IRRITANT. Irritating to eyes, respiratory system and skin.
11. Wipe bottom of plate free of residual liquid and/or fingerprints that can alter optical density (OD) readings.
12. Dilution or adulteration of these reagents may generate erroneous results.
13. Reagents from other sources or manufacturers should not be used.

**Revised 11 Mar. 2008 (Vers. 1.1)**



14. TMB Solution should be colorless, very pale yellow, very pale green, or very pale blue when used. Contamination of the TMB with conjugate or other oxidants will cause the solution to change color prematurely. Do not use the TMB if it is noticeably blue in color. Never pipette by mouth. Avoid contact of reagents and patient specimens with skin and mucous membranes.
15. Avoid microbial contamination of reagents. Incorrect results may occur.
16. Cross contamination of reagents and/or samples could cause erroneous results
17. Reusable glassware must be washed and thoroughly rinsed free of all detergents.
18. Avoid splashing or generation of aerosols.
19. Do not expose reagents to strong light during storage or incubation.
20. Allowing the microwell strips and holder to equilibrate to room temperature prior to opening the protective envelope will protect the wells from condensation.
21. Wash solution should be collected in a disposal basin. Treat the waste solution with 10% household bleach (0.5% sodium hypochlorite). Avoid exposure of reagents to bleach fumes.
22. Caution: Liquid waste at acid pH should be neutralized before adding to bleach solution.
23. Do not use ELISA plate if the indicator strip on the desiccant pouch has turned from blue to pink.
24. Do not allow the conjugate to come in contact with containers or instruments that may have previously contained a solution utilizing sodium azide as a preservative. Residual amounts of sodium azide may destroy the conjugate's enzymatic activity.
25. Do not expose any of the reactive reagents to bleach-containing solutions or to any strong odors from bleach-containing solutions. Trace amounts of bleach (sodium hypochlorite) may destroy the biological activity of many of the reactive reagents within this kit.

**MATERIALS REQUIRED BUT NOT PROVIDED:**

- ELISA microwell reader capable of reading at a wavelength of 450nm.
- Pipettes capable of accurately delivering 10 to 200/ $\mu$ L
- Multichannel pipette capable of accurately delivering (50-200/ $\mu$ L)
- Reagent reservoirs for multichannel pipettes.
- Wash bottle or microwell washing system.
- Distilled or deionized water.
- One liter graduated cylinder.
- Serological pipettes.
- Disposable pipette tips.
- Paper towels.
- Laboratory timer to monitor incubation steps.
- Disposal basin and disinfectant, (example: 10% household bleach, 0.5% sodium hypochlorite.)

**Revised 11 Mar. 2008 (Vers. 1.1)****STORAGE CONDITIONS**

1. Store the unopened kit between 2° and 8°C.
2. Coated microwell strips: Store between 2° and 8°C. Extra strips should be immediately resealed with desiccant and returned to proper storage. Strips are stable for 60 days after the envelope has been opened and properly resealed and the indicator strip on the desiccant pouch remains blue.
3. Conjugate: Store between 2° and 8°C. DO NOT FREEZE.
4. Calibrator, Positive Control and Negative Control: Store between 2° and 8°C.
5. Absorbent Solution: Store between 2° and 8°C
6. TMB: Store between 2° and 8°C.
7. Wash Buffer concentrate (10X): Store between 2° and 25°C. Diluted wash buffer (1X) is stable at room temperature (20° to 25° C) for up to 7 days or for 30 days between 2° and 8°C.
8. Sample Diluent: Store between 2° and 8°C.
9. Stop Solution: Store between 2° and 25°C.

**SPECIMEN COLLECTION**

1. It is recommended that specimen collection be carried out in accordance with NCCLS document M29: Protection of Laboratory Workers from Infectious Disease.
2. No known test method can offer complete assurance that human blood samples will not transmit infection. Therefore, all blood derivatives should be considered potentially infectious.
3. Only freshly drawn and properly refrigerated sera obtained by approved aseptic venipuncture procedures should be used in this assay (6, 7). No anticoagulants or preservatives should be added. Avoid using hemolyzed, lipemic, or bacterially contaminated sera.
4. Store sample at room temperature for no longer than 8 hours. If testing is not performed within 8 hours, sera may be stored between 2° and 8°C for no longer than 48 hours. If delay in testing is anticipated, store test sera at -20°C or lower. Avoid multiple freeze/thaw cycles that may cause loss of antibody activity and give erroneous results.

**GENERAL PROCEDURE**

1. Remove the individual components from storage and allow them to warm to room temperature (20-25°C).
2. Determine the number of microwells needed. Allow six Control/Calibrator determinations (one Blank, one Negative Control, three Calibrators and one Positive Control) per run. A Reagent Blank should be run on each assay. Check software and reader requirements for the correct Controls/Calibrator configurations. Return unused strips to the resealable pouch with desiccant, seal, and return to storage between 2° and 8°C.

**Revised 11 Mar. 2008 (Vers. 1.1)**


EXAMPLE PLATE SET-UP		
	1	2
A	Blank	Patient 3
B	Neg. Control	Patient 4
C	Calibrator	Etc.
D	Calibrator	
E	Calibrator	
F	Pos. Control	
G	Patient 1	
H	Patient 2	

3. Prepare a 1:21 dilution (e.g.: 10µL of serum + 200µL of Sample Diluent. NOTE: Shake Well Before Use) of the Negative Control, Calibrator, Positive Control, and each patient serum.
4. Add 100µL Absorbent solution to the appropriate wells of a blank dilution plate. Using a multichannel pipette, transfer 50µL of each diluted sample and control serum to the dilution plate containing the Absorbent. Withdraw and expel the samples several times to ensure that the samples are properly mixed.
5. To individual wells, add 100µL of each diluted control, calibrator and sample from the absorption plate to the test plate. Ensure that the samples are properly mixed. Use a different pipette tip for each sample.
6. Add 100µL of Sample Diluent to well A1 as a reagent blank. Check software and reader requirements for the correct reagent blank well configuration.
7. Incubate the plate at room temperature (20-25°C) for 25 ± 5 minutes.
8. Wash the microwell strips 5X.
  - A. Manual Wash Procedure:
    - a. Vigorously shake out the liquid from the wells.
    - b. Fill each microwell with Wash Buffer. Make sure no air bubbles are trapped in the wells.
    - c. Repeat steps a. and b. for a total of 5 washes.
    - d. Shake out the wash solution from all the wells. Invert the plate over a paper towel and tap firmly to remove any residual wash solution from the wells. Visually inspect the plate to ensure that no residual wash solution remains. Collect wash solution in a disposable basin and treat with 0.5% sodium hypochlorite (bleach) at the end of the days run.
  - B. Automated Wash Procedure:

If using an automated microwell wash system, set the dispensing volume to 300-350µL/well. Set the wash cycle for 5 washes with no delay between washes. If necessary, the microwell plate may be removed from the washer, inverted over a paper towel and tapped firmly to remove any residual wash solution from the microwells.
9. Add 100µL of the Conjugate to each well, including reagent blank well, at the same rate and in the same order as the specimens were added.
10. Incubate the plate at room temperature (20-25°C) for 25 ± 5 minutes



Revised 11 Mar. 2008 (Vers. 1.1)



11. Wash the microwells by following the procedure as described in step 8.
12. Add 100µL of TMB to each well, including reagent blank well, at the same rate and in the same order as the specimens were added.
13. Incubate the plate at room temperature (20-25°C) for 10 to 15 minutes.
14. Stop the reaction by adding 50µL of Stop Solution to each well, including reagent blank well, at the same rate and in the same order as the TMB was added. Positive samples will turn from blue to yellow. After adding the Stop Solution, tap the plate several times to ensure that the samples are thoroughly mixed.
15. Set the microwell reader to read at a wavelength of 450nm and measure the optical density (OD) of each well against the reagent blank. The plate should be read within 30 minutes after the addition of the Stop Solution.

## QUALITY CONTROL

1. Each time the assay is run the Calibrator must be run in triplicate. A reagent blank, Negative Control, and Positive Control must also be included in each assay.
2. Calculate the mean of the three Calibrator wells. If any of the three values differ by more than 15% from the mean, discard that value and calculate the mean using the remaining two wells.
3. The mean OD value for the Calibrator and the OD values for the Positive and Negative Controls should fall within the following ranges:

	<u>OD Range</u>
Negative Control	< 0.250
Calibrator	> 0.300
Positive Control	> 0.500

- a. The OD of the Negative Control divided by the mean OD of the Calibrator should be < 0.9.
  - b. The OD of the Positive Control divided by the mean OD of the Calibrator should be > 1.25.
  - c. If the above conditions are not met the test should be considered invalid and should be repeated.
4. The Positive Control and Negative Control are intended to monitor for substantial reagent failure and will not ensure precision at the assay cut-off.
  5. Additional controls may be tested according to guidelines or requirements of local, state, and/or federal regulations or accrediting organizations.
  6. Refer to NCCLS document C24: Statistical Quality Control for Quantitative Measurements for guidance on appropriate QC practices.

## INTERPRETATION OF RESULTS

### A. Calculations:

#### 1. Correction Factor

A cutoff OD value for positive samples has been determined by the manufacturer and correlated to the Calibrator. The correction factor (CF) will allow you to determine the cutoff value for positive samples and to

Revised 11 Mar. 2008 (Vers. 1.1)



correct for slight day-to-day variations in test results. The correction factor is determined for each lot of kit components and is printed on the data label located in the kit box.

## 2. Cutoff OD Value

To obtain the cutoff OD value, multiply the CF by the mean OD of the Calibrator determined above.  
(CF x mean OD of Calibrator = cutoff OD value)

## 3. Index Values or OD Ratios

Calculate the Index Value or OD Ratio for each specimen by dividing its OD value by the cutoff OD from step 2.

### Example:

Mean OD of Calibrator	=	0.793
Correction Factor (CF)	=	0.25
Cut off OD	=	$0.793 \times 0.25 = 0.198$
Unknown Specimen OD	=	0.432
Specimen Index Value or OD Ratio	=	$0.432 / 0.198 = 2.18$

Index Values or OD ratios are interpreted as follows:

	<u>Index Value or OD Ratio</u>
Negative Specimens	< 0.90
Equivocal Specimens	0.91 to 1.09
Positive Specimens	> 1.10

## B. Interpretations:

The OD ratio is interpreted and reported as follows:

Negative: No detectable IgM antibody; result does not exclude *B. burgdorferi* infection. An additional sample should be tested within 4-6 weeks if early infection is suspected (8).

Equivocal: Current recommendations state that equivocal results should be followed by supplemental Western Blot testing. (Western Blot assays for antibodies to *B. burgdorferi* are supplemental rather than confirmatory because their specificity is less than optimal, particularly for detecting IgM.) This equivocal result should be reported with results from Western Blot testing. Results should not be reported until the supplemental testing is completed.

Positive: IgM antibody to *B. burgdorferi* presumptively detected. Per current recommendations, the result cannot be further interpreted without supplemental Western Blot testing. (Western Blot assays for antibodies to *B. burgdorferi* are supplemental rather than confirmatory because their specificity is less than optimal, particularly for detecting IgM.) Results should not be reported until the supplemental testing is completed.



**Revised 11 Mar. 2008 (Vers. 1.1)****LIMITATION OF THE ASSAY**

1. Sera from patients with other spirochetal diseases (syphilis, yaws, pinta, leptospirosis, and relapsing fever), and infectious mononucleosis may give false positive results (9, 10). In cases where false positive reactions are observed, extensive clinical epidemiological and laboratory workups should be carried out to determine the specific diagnosis. False positive sera from syphilis patients can be identified by running an RPR and a Treponemal antibody assay for syphilis antibody (11). True Lyme disease positive sera will be negative in these assays.
2. False negative results may be obtained if serum samples are drawn too early after onset of disease before antibody levels have reached significant levels (12). Also, early antibiotic therapy may abort an antibody response to the spirochete (13).
3. AH data should be interpreted in conjunction with clinical symptoms of disease, epidemiological data, exposure in endemic areas, and results of other laboratory tests.
4. Rheumatoid factor may cause false positive results.
5. Screening of the general population should not be performed. The positive predictive value depends on the pretest likelihood of infection. Testing should only be performed when clinical symptoms are present or exposure is suspected.
6. The performance characteristics of the Zeus B. burgdorferi IgM ELISA test are not established with samples from individuals vaccinated with B. burgdorferi antigens.

**EXPECTED VALUES**

Only 10 to 40% of patients with ECM alone have detectable levels of antibody to B. burgdorferi (3,12,14). The IgM antibody response usually peaks from 3 to 6 weeks following infection, and is often not detectable during the first two weeks of infection. The IgG antibody response is frequently not detectable for 4 to 6 weeks after infection. A more complete serological picture may be obtained by testing acute and convalescent sera. Most patients (94-97%) with neurological complications, and essentially all patients with arthritis have elevated IgG titers to the spirochete (14,15). In later stages, a positive antibody test may help distinguish Lyme disease from viral meningitis or unexplained nerve palsies. A positive antibody test may be particularly useful in differentiating Lyme arthritis from rheumatoid arthritis, juvenile arthritis, and Reiter's Syndrome (13). Patients without signs or clinical features of Lyme disease should test negative with the Zeus Borrelia burgdorferi IgM ELISA test system.

Revised 11 Mar. 2008 (Vers. 1.1)



## PERFORMANCE CHARACTERISTICS

### A. Comparative Study

#### STUDY NO. 1

The *Borrelia burgdorferi* IgM ELISA test system was compared to a commercially available ELISA test for detection of IgM antibodies to *B. burgdorferi*. A total of 210 serum specimens were tested by both procedures. The test results are summarized below:

		Reference EUSA		
		+	-	±*
Zeus <i>Borrelia burgdorferi</i> IgM ELISA	+	42	11	2
	-	2	136	4
	±*	3	8	2

Relative Sensitivity = 95.5% (42/44)

Relative Specificity = 92.5% (136/147)

Agreement = 93.1%(178/191)

\*Results that were equivocal by either method were excluded from the calculations for sensitivity, specificity, and agreement.

#### STUDY NO. 2

This study was done in the clinical immunology laboratory at a medical school. Twenty-one sera from patients with acute and convalescent Lyme disease were tested by the IgM ELISA. The patient sera were well characterized by a recognized authority. Acute phase (Stage 1) sera were from patients with a characteristic ECM skin rash. Convalescent sera had characteristic symptoms of Stage 2 or Stage 3 Lyme disease. As part of this study, the sera were also tested by five other commercial *Borrelia burgdorferi* IgG/IgM, and IgG specific ELISA assays. Results for the six ELISA assays are summarized below:

Revised 11 Mar. 2008 (Vers. 1.1)



ELISA ASSAY FOR:		IgG/IgM		IgG		ZEUS IgM	
Sample No.	Disease Stage	Test 1	Test 2	Test 3	Test 4	Test 5	Test 6
1	1	+	+	+	+	-	+
2	1	+	+	+	+	-	+
3	1	-	-	-	-	-	-
4	1		-	-	+	-	+
5	1	-	-	-	-	-	-
6	1	+	+	+	+	±	+
7	1	+	+	+	+	+	+
8	2	+	+	+	+	+	+
9	2	+	+	+	±	+	-
10	2	+	+	+	+	+	+
11	2	+	+	-	+	+	±
12	2	+	+	+	+	+	+
13	2	+	+	+	+	+	+
14	2	+	+	+	+	+	-
15	3	+	+	+	+	+	+
16	3	+	+	+	+	+	-
17	3	+	+	+	+	+	-
18	3	+	+	+	±	+	-
19	3	+	+	+	+	+	-
20	3	+	+	+	+	+	+
21	3	+	+	+	+	+	-

Table 1 shows test results obtained using a serum panel from the CDC. The results are presented as a means to convey further information on the performance of this assay with a masked, characterized serum panel. This does not imply an endorsement of the assay by the CDC.

Revised 11 Mar. 2008 (Vers. 1.1)



Tablet. The CDC 8. burgdorferi Disease Serum Panel Stratified by Time After Onset					
Time from onset	Pos	+/-	Neg	Total	% agreement with clinical diagnosis
Normals	0	0	5	5	100%
< 1 month	3	0	2	5	60%
1-2 months	7	0	2	9	78%
3- 12 months	5	0	15	20	25%
> 1 year	1	0	7	8	12%
Total	16	0	31	47	45%

### B. Reproducibility

To assess the reproducibility of the test system, six serum samples were tested on three consecutive days. Eight replicates of each serum sample were run each day.

The mean OD ratio and coefficient of variation (CV) were calculated for each sample. These data are shown below:

			Intra- Assay (n=8)			Inter-Assay (n=3)		
			Day 1		Day 2		Day 3	
Sample No.	Mean Ratio	CV	Mean Ratio	CV	Mean Ratio	CV	Mean Ratio	CV
1.	1.63	3%	1.69	4%	1.43	6%	1.60	6%
2.	1.72	7%	1.80	6%	1.53	9%	1.68	7%
3.	1.33	8%	1.42	5%	1.21	5%	1.32	7%
4.	1.07	3%	1.29	4%	1.02	6%	1.13	10%
5.	0.85	7%	0.99	5%	0.89	7%	0.91	6%
6.	0.21	11%	0.26	14%	0.22	5%	0.24	13%

### C. Cross Reactivity

Serum specimens from patients with North American borreliosis, yaws, pinta, leptospirosis, autoimmune diseases, and syphilis may crossreact (14).

Ten sera with IFA titers of 1:80 to 1:1280 for antibodies to nuclear antigens (ANA) were negative in the B. burgdorferi IgM ELISA test.

**Revised 11 Mar. 2008 (Vers. 1.1)****REFERENCES**

1. Steere AC, Taylor E, Wilson ML, Levine JF, and Spielman A: Longitudinal assessment of the clinical and epidemiological features of Lyme disease in a defined population. *J. Infect. Dis.* 154:295-300, 1986.
2. Rosenfeld MEA: Serodiagnosis of Lyme disease. *J. Clin. Microbiol.* 31:3090-3095, 1993.
3. Steere AC, Grodzicki RL, Kornblatt AN, Craft JE, Barbour AG, Burgdorfer W, Schmid GP, Johnson E, and Marawista SE: The spirochetal etiology of Lyme disease. *New Engl. J. Med.* 308:733, 1983.
4. Bakken LL, Callister SM, Wand PJ, and Schell RF: Interlaboratory comparison of test results for detection of Lyme disease by 516 patients in the Wisconsin State Laboratory of Hygiene/College of American Pathologists Proficiency Testing Program. *J. Clin. Microbiol.* 35:537-543, 1997.
5. U.S. Department of Labor (OSHA): Occupational Exposure to Bloodborne Pathogens. Final Rule. 21CFR 1910.1030.
6. Procedures for the Handling and Processing of Blood Specimens: NCCLS Procedure H18. Approved guideline.
7. Procedures for the collection of diagnostic blood specimens by venipuncture: NCCLS Procedure H3, Approved Standard.
8. Barbour A: Laboratory Aspects of Lyme Borreliosis. *Clin. Microb. Rev.* 1:399-414, 1988.
9. Russel H, Sampson JS, Schmid GP, Wilkinson HW, and Plikaytis B: Enzyme-linked immunosorbent assay and indirect immunofluorescence assay for Lyme disease. *J. Infect. Dis.* 149:465, 1984.
10. Magnarelli LA, Anderson JF, and Johnson RC: Cross-reactivity in serological test for Lyme disease and other spirochetal infections. *J. Infect. Dis.* 156:183-188, 1987.
11. Hunter EF, Russell H, et al: Evaluation of sera from patients with Lyme disease in the fluorescent treponeme antibody-absorption test for syphilis. *Sex. Trans. Dis.* 13:236, 1986.
12. Shrestha M, Grodzicki RL, and Steere AC: Diagnosing early Lyme disease. *Am. J. Med.* 78:235, 1985.
13. Steere AC, Hutchinson GJ, Rahn DW, Sigal LJH, Craft JE, DeSanna ET, and Malawist SE: Treatment of the early manifestations of Lyme disease. *Ann. Intern. Med.* 99:22, 1983.
14. Craft JE, Grodzicki RL, Shrestha M, Fischer DK, Garcia-Bianco M, and Steer AC: Antibody response in Lyme disease. *Yale J. Biol. Med.* 57:561, 1984.
15. Reik L, Smith L, Khan A, and Nelson W: Demyelinating encephalopathy in Lyme disease. *Neurology* 35:267, 1985.

Version 031507 ~pm.